Business
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty Canada NewsWi...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n Equity Insider\n \n\n\n News Commentary\n \n\n\n\n\n Issued on behalf of Oncolytics Biotech Inc.\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n May 1, 2025\n \n\n /CNW/ --\n \n\n Equity Insider\n \n\n\n News Commentary\n \n – Optimism in the field of oncology is on the rise, thanks to the\n \n National Institutes of Health's\n \n latest\n \n annual report\n \n , which showed a\n \n steady decline in cancer death rates\n \n . However, incidence\n \n rates and diagnoses are on the rise\n \n , meaning the need for better treatment and earlier screening remains. With potential\n \n NIH\n \n\n budget reductions under discussion\n \n and new projections indicating that drug tariffs could raise treatment costs by\n \n over\n \n $10,000\n \n\n , the future of innovation may increasingly depend on private-sector initiatives rather than government support. Several oncology innovators have already delivered notable updates in 2025, among them\n \n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC),\n \n Sutro Biopharma, Inc.\n \n (NASDAQ: STRO),\n \n BriaCell Therapeutics Corp.\n \n (NASDAQ: BCTX) (NASDAQ: BCTXW) (TSX: BCT),\n \n Tempus AI, Inc.\n \n (NASDAQ: TEM) and\n \n AstraZeneca PLC\n \n (NASDAQ: AZN).\n \n\n\n\n\n\n\n\n\n In general, cancer incidence is projected to rise significantly, with global cases expected to\n \n increase by 20% by 2030 and surge 75% by 2050\n \n , according to\n \n Statista\n \n . In parallel,\n \n Precedence Research\n \n estimates that the global market for immunotherapy drugs could\n \n approach\n \n US$1.2 trillion\n \n by 2033\n \n , supported by a robust 18% compound annual growth rate.\n \n\n\n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC)\n \n just confirmed\n \n that it will present new pancreatic cancer data at the upcoming ASCO Annual Meeting in\n \n Chicago\n \n , highlighting how pelareorep, its intravenously delivered immunotherapy, activa...